GlassScriptPhysician profile
Dezy Mani
NPI 1235704750
$5,994.22
in general payments reported to CMS, 2019-2025
26 companies · $911 in 2025
The $911 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.86 · 2022: $294 · 2023: $2,705 · 2024: $2,062 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556 · Travel and Lodging: $2,032 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.88 |
| Travel and Lodging | $2,032.41 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,319.49 | 2023-2024 | Synchromedii, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,250.35 | 2022-2025 | Relistor |
| Virtus Pharmaceuticals LLC | $292.16 | 2023-2025 | Levorphanol Tartrate |
| Collegium Pharmaceutical, INC. | $172.14 | 2023-2025 | Belbuca, Xtampza |
| Lundbeck LLC | $122.07 | 2023-2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $111.65 | 2022-2025 | Ztlido |
| Protega Pharmaceutials INC | $99.97 | 2025 | Roxybond |
| Sobi, INC | $63.13 | 2021-2022 | |
| Saluda Medical Americas, INC. | $58.44 | 2025 | Evoke |
| Nalu Medical, INC. | $51.74 | 2025 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $50.96 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Valinor Pharma, LLC | $43.22 | 2024 | Movantik |
| Painteq LLC | $38.64 | 2024 | Painteq |
| Merz Pharmaceuticals, LLC | $36.96 | 2023 | Xeomin |
| Merck Sharp & Dohme LLC | $36.60 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.07 | 2022 | |
| Pfizer INC. | $28.98 | 2024 | |
| Phadia US INC. | $24.76 | 2022 | |
| Spinal Simplicity, LLC | $22.66 | 2025 | Ha Minuteman G3-R |
| Ipsen Biopharmaceuticals, INC | $21.61 | 2024 | Dysport |
| Tersera Therapeutics LLC | $21.09 | 2023 | Prialt |
| Electronic Waveform Lab, INC. | $20.10 | 2025 | |
| Vision Quest Industries INC. | $20.03 | 2024 | Avid Ct2 Nmes/Ifc Stimulator |
| Sanofi Pasteur INC. | $19.30 | 2022 | |
| Axsome Therapeutics, INC. | $18.33 | 2025 | Symbravo |
| Cranial Technologies, INC | $16.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dezy Mani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.